Two federal lawmakers have introduced a bill seeking to apply the review requi | Two federal lawmakers have introduced a bill seeking to apply the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act to investments in Chinese biotechnology.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
House bill aims to crack down on China biotech deals
In Washington, biotech's China hawks are winning the conversation
Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech
US lawmakers reveal policy to curb collaboration with Chinese biotech - Pharmaceutical Technology
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block…
The skyrocketing use of Chinese biopharmas as a source of innovation for U.S. drug developers has been viewed with alarm among…
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S.…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink…
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall…
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic…
